Combination of an insulin and a glp-1-agonist

Abstract

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

1 . A pharmaceutical composition comprising at least one insulin and at least one GLP-1 agonist, and pharmaceutically acceptable salts thereof, wherein said pharmaceutical composition comprises the insulin and the GLP-1 agonist each in a predetermined amount, and is administered in a dose adapted to the individual requirement of a patient. 
     
     
         2 . The pharmaceutical composition of  claim 1 , comprising a first composition and a second composition, wherein each composition comprises at least one insulin and at least one GLP-1 agonist in different weight fractions relative to the total weight of the composition. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the weight fractions of the at least one insulin and of the at least one GLP-1 agonist in the first composition and the second composition are selected such that the pharmaceutical compositions contain different proportions of insulin to GLP-1 agonist, based on the weight fraction. 
     
     
         4 . The pharmaceutical composition of  claim 2 , wherein each composition comprises the at least one insulin in a substantially identical weight fraction and the at least one GLP-1 agonist in different weight fractions. 
     
     
         5 . The pharmaceutical composition of  claim 2 , wherein each composition comprises the at least one GLP-1 agonist in a substantially identical weight fraction and the at least one insulin in different weight fractions. 
     
     
         6 . The pharmaceutical composition of  claim 2 , wherein the first composition comprises at least one insulin and the second composition comprises at least one GLP-1 agonist, and wherein the pharmaceutical composition is formulated for the independent administration of the first and second compositions. 
     
     
         7 . The pharmaceutical composition as claimed in  claim 6 , wherein the first composition, the second composition comprise the insulin in substantially identical weight fractions relative to the total weight of the composition. 
     
     
         8 . The pharmaceutical composition as claimed in  claim 1 , wherein the at least one insulin is independently selected from human insulins, analogs, derivatives, and metabolites thereof. 
     
     
         9 . The pharmaceutical composition as claimed in  claim 1 , wherein the at least one GLP-1 agonist is selected from the group consisting of GLP-1, analogs and derivatives thereof, exendin-3, analogs and derivatives thereof, exendin-4, analogs and derivatives thereof, and pharmacologically tolerable salts thereof. 
     
     
         10 . A method of treating a patient with the pharmaceutical composition of  claim 7  comprising:
 (i.) selecting a dose of the at least one insulin that is to be administered, and determining the total amount of the first composition and second composition such that the selected dose of the at least one insulin is present in the total amount, 
 (ii.) selecting a dose of the at least one GLP-1 agonist that is to be administered and determining the amount of the second composition such that the selected dose of the at least one GLP-1 agonist is present in the amount of the second composition, 
 (iii.) administering an amount of the first composition to the patient, the administered amount corresponding to the total amount as per step (i) minus the amount of the second composition as per step (ii); and 
 (iv.) administering the amount of the second composition that was determined in step (ii) to the patient. 
 
     
     
         11 . The method of  claim 10 , wherein said patient is treated for adjusting the fasting, postprandial and/or postabsorptive blood glucose concentration, for improving glucose tolerance, for preventing hypoglycemia, for preventing loss of function of the pancreatic β-cells, for weight loss and/or preventing weight gain. 
     
     
         12 . The method of  claim 10 , wherein said patient is treated for type 1 or type 2 diabetes. 
     
     
         13 . A device comprising the pharmaceutical composition of  claim 2 , wherein the first and second compositions are in separate containers to allow the dosing of the compositions independently of one another. 
     
     
         14 . The device of  claim 13 , wherein the device is an injection pen.